EFT BioTech Holdings, Inc.’s Sea Vessel
Completes Inaugural Passenger Voyage Across the Taiwan Strait
-- The 2,292-ton Ocean Lala sailed from the Taichung Harbor
to Xiamen, China and carried 179 passengers and 23 crew members--
CITY OF INDUSTRY, CA and HONG KONG--(PRNewswire)—June 30, 2009 -- EFT BioTech Holdings, Inc. (OTC Pink Sheets: EFTB.PK ) announced today that the Company’s subsidiary, Excalibur Marine Corporation, completed its inaugural passenger voyage across the Taiwan Strait on June 28, 2009. The voyage across the Taiwan Strait takes only 4 ½ hours, but it took Taiwan and China 60 years to ease tension and for Taipei to agree to lift the ban on sea links with China’s mainland.
The voyage was featured in a news article that has run in several internet news sites, including the Taiwan Sun and the Qatar Tribune. Jack Qin, the President and CEO of EFT BioTech Holdings, Inc., stated, “We are excited to be recognized by the regional press and this coverage shows that people are truly interested in this much needed passenger and cargo service.”
In October 2008, EFT, through a wholly-owned subsidiary, EFT Investment Company Ltd. purchased a 49% interest in Excalibur International Marine Corporation.
About EFT BioTech Holdings, Inc.
EFT BioTech Holdings, Inc. is a Nevada holding company which conducts its business through its wholly-owned subsidiary, EFT Biotech, Inc., and its wholly owned subsidiaries and various vested interests. EFT BioTech Holdings, Inc. is a B2B e-commerce company serving consumers with EFT's "made in USA" neutraceuticals, health and beauty EFT branded products through its proprietary online business platform and website, www.eftb.us. Although our products are available for sale throughout the world, most Affiliates and consumers are located in China and Hong Kong. The contents of the Company's website are not incorporated by reference herein. The contents of our website are not incorporated by reference herein.
Safe Harbor for Forward-Looking Statements
Statements made in this release with the respect to the Company's current plans, estimates, strategies and beliefs and other statements that are not historical are forward-looking statements. Forward-looking statements include, but are not limited to, those statements using words such as "believe," "expect," "plans," "strategy," prospects," "forecast," "estimate," "project," "anticipate," "aim," "may" or "might" and words of similar meaning in connection with a discussion of future operations, financial performance, vents or conditions. From time to time, oral or written forward-looking statements may also be included in other materials released to the public. These statements are based on management's assumptions and belief in light of the information currently available to it. The company cautions you that a number of important risks and uncertainties could cause actual results to materially differ from those discussed in the forward-looking statements, and therefore, you should not place undue reliance on them. You also should not rely on any obligation of the Company to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The company disclaims any such obligation unless required by law. Risks and uncertainties that might affect the Company include, but are not limited to (i) the global economic environment in which the Company operates, as well as the economic conditions in the Company's markets, (ii) levels of consumer spending, and (iii) exchange rates, particularly between the Chinese Yen and the U.S. Dollar. Risks and uncertainties also include the impact of any future events with material adverse impacts.
For More Information, Please Contact:
Aero Strategic Advisory, A division of Aero Financial, Inc.
Ed Carter
Telephone: 702-982-7732
Source: EFT BioTech Holdings, Inc.
